Hybrid data-based modelling in oncology: successes, challenges and hopes

In this review we make the statement that hybrid models in oncology are required as a mean for enhanced data integration. In the context of systems oncology, experimental and clinical data need to be at the heart of the models developments from conception to validation to ensure a relevant use of the models in the clinical context. The main applications pursued are to improve diagnosis and to optimize therapies.We first present the Successes achieved thanks to hybrid modelling approaches to advance knowledge, treatments or drug discovery. Then we present the Challenges than need to be addressed to allow for a better integration of the model parts and of the data into the models. And Finally, the Hopes with a focus towards making personalised medicine a reality. Mathematics Subject Classification. 35Q92, 68U20, 68T05, 92-08, 92B05.

[1]  Thomas E. Yankeelov,et al.  Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success , 2016, Annals of Biomedical Engineering.

[2]  David A. Rand,et al.  Systems Chronotherapeutics , 2017, Pharmacological Reviews.

[3]  Mark A. J. Chaplain,et al.  Integrating Intracellular Dynamics Using CompuCell3D and Bionetsolver: Applications to Multiscale Modelling of Cancer Cell Growth and Invasion , 2012, PloS one.

[4]  Philipp M. Altrock,et al.  The mathematics of cancer: integrating quantitative models , 2015, Nature Reviews Cancer.

[5]  Angela M. Jarrett,et al.  Mathematical models of tumor cell proliferation: A review of the literature , 2018, Expert review of anticancer therapy.

[6]  D. Huh,et al.  Organs-on-chips at the frontiers of drug discovery , 2015, Nature Reviews Drug Discovery.

[7]  C. Sonnenschein,et al.  Carcinogenesis explained within the context of a theory of organisms. , 2016, Progress in biophysics and molecular biology.

[8]  Vitaly Volpert,et al.  A Hybrid Computation Model to Describe the Progression of Multiple Myeloma and Its Intra-Clonal Heterogeneity , 2017, Comput..

[9]  H. Naci,et al.  Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 , 2017, British Medical Journal.

[10]  Albert Lai,et al.  Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. , 2009, Cancer research.

[11]  Abbas Shirinifard,et al.  Multi-scale modeling of tissues using CompuCell3D. , 2012, Methods in cell biology.

[12]  Florence Tama,et al.  Steered Molecular Dynamics Simulations of a Type IV Pilus Probe Initial Stages of a Force-Induced Conformational Transition , 2013, PLoS Comput. Biol..

[13]  Kimberly R. Kanigel Winner,et al.  Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer. , 2016, Cancer research.

[14]  Glazier,et al.  Simulation of biological cell sorting using a two-dimensional extended Potts model. , 1992, Physical review letters.

[15]  Helen M. Byrne,et al.  Microvessel Chaste: An Open Library for Spatial Modeling of Vascularized Tissues , 2017, Biophysical journal.

[16]  Angélique Stéphanou,et al.  On the importance of the submicrovascular network in a computational model of tumour growth. , 2012, Microvascular research.

[17]  V. Volpert,et al.  Hybrid Modelling in Biology: a Classification Review , 2016 .

[18]  J. Gallo,et al.  Multiscale Design of Cell-Type–Specific Pharmacokinetic/Pharmacodynamic Models for Personalized Medicine: Application to Temozolomide in Brain Tumors , 2014, CPT: pharmacometrics & systems pharmacology.

[19]  A. Lefor.  Computational oncology. , 2011, Japanese journal of clinical oncology.

[20]  Laird Ak.  DYNAMICS OF TUMOR GROWTH. , 1964 .

[21]  Edmond Jonckheere,et al.  Progress Towards Computational 3-D Multicellular Systems Biology. , 2016, Advances in experimental medicine and biology.

[22]  Alberto Rainer,et al.  Microfluidic Organ/Body-on-a-Chip Devices at the Convergence of Biology and Microengineering , 2015, Sensors.

[23]  Alexander G. Fletcher,et al.  Chaste: A test-driven approach to software development for biological modelling , 2009, Comput. Phys. Commun..

[24]  David Basanta,et al.  Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer , 2016, Scientific Reports.

[25]  Robert A Gatenby,et al.  Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies , 2017, bioRxiv.

[26]  Thomas E Yankeelov,et al.  Integrating Imaging Data into Predictive Biomathematical and Biophysical Models of Cancer. , 2012, ISRN biomathematics.

[27]  Roeland M. H. Merks,et al.  Computational Screening of Tip and Stalk Cell Behavior Proposes a Role for Apelin Signaling in Sprout Progression , 2014, PloS one.

[28]  Eric Fanchon,et al.  Systems Biology, Systems Medicine, Systems Pharmacology: The What and The Why , 2018, Acta Biotheoretica.

[29]  Kristin R. Swanson,et al.  Patient-Specific Mathematical Neuro-Oncology: Using a Simple Proliferation and Invasion Tumor Model to Inform Clinical Practice , 2015, Bulletin of mathematical biology.

[30]  Randy Heiland,et al.  PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems , 2017, bioRxiv.

[31]  Rainer Breitling,et al.  What is Systems Biology? , 2010, Front. Physiology.

[32]  A. Anderson,et al.  Evolution of cell motility in an individual-based model of tumour growth. , 2009, Journal of theoretical biology.

[33]  S Nill,et al.  Combining radiation with hyperthermia: a multiscale model informed by in vitro experiments , 2018, Journal of The Royal Society Interface.

[34]  Gary R. Mirams,et al.  An integrative computational model for intestinal tissue renewal , 2009, Cell proliferation.

[35]  P ? ? ? ? ? ? ? % ? ? ? ? , 1991 .

[36]  M. Bizzarri,et al.  SMT and TOFT: Why and How They are Opposite and Incompatible Paradigms , 2016, Acta biotheoretica.

[37]  A. Whiten,et al.  Prestige Affects Cultural Learning in Chimpanzees , 2010, PloS one.

[38]  M. A. J. Chaplain,et al.  The mathematical modelling of tumour angiogenesis and invasion , 1995, Acta biotheoretica.

[39]  M. Koury,et al.  Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis , 2016, American journal of hematology.

[40]  Kujtim Latifi,et al.  A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation , 2015, Radiation Oncology.

[41]  Samuel Bernard,et al.  Hybrid Model of Erythropoiesis and Leukemia Treatment with Cytosine Arabinoside , 2011, SIAM J. Appl. Math..

[42]  F. Michor,et al.  Evolution of acquired resistance to anti-cancer therapy. , 2014, Journal of theoretical biology.

[43]  Marco Alberto Javarone,et al.  Modeling Radicalization Phenomena in Heterogeneous Populations , 2015, PloS one.

[44]  S. Ruphy,et al.  SMT or TOFT? How the Two Main Theories of Carcinogenesis are Made (Artificially) Incompatible , 2015, Acta biotheoretica.

[45]  Gibin G. Powathil,et al.  What does not kill a tumour may make it stronger: in silico Insights on Chemotherapeutic Drug Resistance , 2017, bioRxiv.

[46]  W. Looney,et al.  Solid tumor models for the assessment of different treatment modalities: I. Radiation-induced changes in growth rate characteristics of a solid tumor model. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Nicolas André,et al.  Computational oncology — mathematical modelling of drug regimens for precision medicine , 2016, Nature Reviews Clinical Oncology.

[48]  Maciej Swat,et al.  Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. , 2015, Seminars in cancer biology.

[49]  Zvia Agur,et al.  Personalizing oncology treatments by predicting drug efficacy, side‐effects, and improved therapy: mathematics, statistics, and their integration , 2014, Wiley interdisciplinary reviews. Systems biology and medicine.

[50]  Marie Martin,et al.  Patient Specific Image Driven Evaluation of the Aggressiveness of Metastases to the Lung , 2014, MICCAI.

[51]  Zhiwei Ji,et al.  Mathematical and Computational Modeling in Complex Biological Systems , 2017, BioMed research international.

[52]  Alexander R. A. Anderson,et al.  Mathematical modelling of flow in 2D and 3D vascular networks: Applications to anti-angiogenic and chemotherapeutic drug strategies , 2005, Math. Comput. Model..

[53]  K. Swanson,et al.  The biology and mathematical modelling of glioma invasion: a review , 2017, Journal of The Royal Society Interface.

[54]  Paolo Magni,et al.  Current mathematical models for cancer drug discovery , 2017, Expert opinion on drug discovery.

[55]  L. Hutchinson,et al.  High drug attrition rates—where are we going wrong? , 2011, Nature Reviews Clinical Oncology.

[56]  Annabelle Ballesta,et al.  Physiologically based mathematical models to optimize therapies against metastatic colorectal cancer: a mini-review. , 2014, Current pharmaceutical design.

[57]  Thomas E. Yankeelov,et al.  Quantitative multimodality imaging in cancer research and therapy , 2014, Nature Reviews Clinical Oncology.

[58]  B. Bedessem,et al.  SMT and TOFT Integrable After All: A Reply to Bizzarri and Cucina , 2017, Acta biotheoretica.

[59]  Yuri Kogan,et al.  Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models , 2010, PloS one.

[60]  Vittorio Cristini,et al.  Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. , 2012, Journal of theoretical biology.

[61]  Heiko Enderling,et al.  Simulating Cancer: Computational Models in Oncology , 2013, Front. Oncol..

[62]  K. Tsuneyama,et al.  Lymphoma-Like T Cell Infiltration in Liver Is Associated with Increased Copy Number of Dominant Negative Form of TGFβ Receptor II , 2012, PloS one.

[63]  M. Pons-Salort,et al.  A Computational Framework to Assess the Efficacy of Cytotoxic Molecules and Vascular Disrupting Agents against Solid Tumours , 2012 .

[64]  F. Estève,et al.  How tumour-induced vascular changes alter angiogenesis: Insights from a computational model. , 2017, Journal of theoretical biology.

[65]  P. Maini,et al.  Mathematical Oncology , 2018, Bulletin of Mathematical Biology.

[66]  David Basanta,et al.  Homeostasis Back and Forth: An Eco-Evolutionary Perspective of Cancer , 2016, bioRxiv.

[67]  Yangjin Kim,et al.  Strategies of Eradicating Glioma Cells: A Multi-Scale Mathematical Model with MiR-451-AMPK-mTOR Control , 2015, PloS one.

[68]  Kujtim Latifi,et al.  Predicting Patient-Specific Radiotherapy Protocols Based on Mathematical Model Choice for Proliferation Saturation Index , 2018, Bulletin of mathematical biology.

[69]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[70]  K. R. Swanson,et al.  From Patient-Specific Mathematical Neuro-Oncology to Precision Medicine , 2013, Front. Oncol..

[71]  A. Pocheville,et al.  The Hitchhiker’s Guide to the Cancer Galaxy: How two critics missed their destination , 2017 .

[72]  Angélique Stéphanou,et al.  Towards the Design of a Patient-Specific Virtual Tumour , 2016, Comput. Math. Methods Medicine.

[73]  Alexander G. Fletcher,et al.  Chaste: An Open Source C++ Library for Computational Physiology and Biology , 2013, PLoS Comput. Biol..

[74]  Aleksandra Karolak,et al.  Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues , 2018, Journal of The Royal Society Interface.

[75]  L. Aarons,et al.  Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients. , 2017, Mathematical medicine and biology : a journal of the IMA.

[76]  Andrea Hawkins-Daarud,et al.  Simulating PDGF-Driven Glioma Growth and Invasion in an Anatomically Accurate Brain Domain , 2018, Bulletin of mathematical biology.

[77]  C. Sonnenschein,et al.  The tissue organization field theory of cancer: A testable replacement for the somatic mutation theory , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[78]  M. Block.  Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps , 2015, Expert opinion on drug metabolism & toxicology.

[79]  Mark A. J. Chaplain,et al.  Bystander effects and their implications for clinical radiation therapy: Insights from multiscale in silico experiments. , 2014, Journal of theoretical biology.